(Q34232030)

31 July 2017

1 reference

title

Inhibitors of platelet signal transduction as anti-aggregatory drugs (English)

1 reference

31 July 2017

1

Geiger J

1 reference

PubMed ID

11322863

31 July 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

Expert Opinion on Investigational Drugs

31 July 2017

1 reference

31 July 2017

10

1 reference

31 July 2017

5

1 reference

31 July 2017

865-890

1 reference

The role of heterotrimeric G proteins in platelet activation

31 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Calcium signaling in human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Reconstitution of thromboxane A2 receptor-stimulated phosphoinositide hydrolysis in isolated platelet membranes: involvement of phosphoinositide-specific phospholipase C-beta and GTP-binding protein Gq.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Nitric oxide and its role in the cardiovascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

The pathogenesis of atherosclerosis: a perspective for the 1990s

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Characterization of Sp-5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole- 3',5'-monophosphorothioate (Sp-5,6-DCl-cBiMPS) as a potent and specific activator of cyclic-AMP-dependent protein kinase in cell extracts and intact cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Analysis of the functional role of cGMP-dependent protein kinase in intact human platelets using a specific activator 8-para-chlorophenylthio-cGMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Role of cGMP and cGMP-dependent protein kinase in nitrovasodilator inhibition of agonist-evoked calcium elevation in human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Endothelium-derived relaxing factor inhibits in vitro platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Endothelium-derived relaxing factor inhibits platelet aggregation in human whole blood in vitro and in the rat in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Sodium nitroprusside and other smooth muscle-relaxants increase cyclic GMP levels in rat ductus deferens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Systemic effects of S-nitroso-glutathione in the human following intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Release of nitric oxide from donors with known half-life: a mathematical model for calculating nitric oxide concentrations in aerobic solutions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Comparison of the effects of prostacyclin (PGI2), prostaglandin E1 and D2 on platelet aggregation in different species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Characterization of the platelet prostaglandin D2 receptor. Loss of prostaglandin D2 receptors in platelets of patients with myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Specific binding sites for prostaglandin D2 on human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Novel antithrombotic drugs in development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans. The TAO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

A dose-effect study of beraprost sodium in intermittent claudication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

The effect of PGI2 analogue on vascular endothelial function and platelet aggregation in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Clinical studies on the vasodilating and anti-platelet effects of OP-41483, a prostacyclin derivative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Spontaneous laser doppler flux distribution in ischemic ulcers and the effect of prostanoids: a crossover study comparing the acute action of prostaglandin E1 and iloprost vs saline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Adenosine-mediated inhibition of platelet aggregation by acadesine. A novel antithrombotic mechanism in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Human blood platelet 3': 5'-cyclic nucleotide phosphodiesterase. Isolation of low-Km and high-Km phosphodiesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Cyclic GMP phosphodiesterase-5: target of sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Clinical evaluation on combined administration of oral prostacyclin analogue beraprost and phosphodiesterase inhibitor cilostazol

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit-risk analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Inositol lipids, phosphatidate and diacylglycerol share stearoylarachidonoylglycerol as a common backbone in thrombin-stimulated human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Prostaglandin endoperoxide synthase: structure and catalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

The eicosanoids and their biochemical mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Acetylation of prostaglandin synthase by aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

The mechanism of action of KBT-3022, a new antiplatelet agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Antithrombotic effects in a rat model of aspirin-insensitive arterial thrombosis of desethyl KBT-3022, the main active metabolite of a new antiplatelet agent, KBT-3022.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Reduction by indobufen of neutrophil activation in peripheral arterial occlusive disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Superiority of platelet integrin GPIIb-IIIa receptor antagonist over aspirin in preventing cyclic flow reductions in the guinea pig middle cerebral artery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase. Thromboregulation by endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Inhibition of platelet function by recombinant soluble ecto-ADPase/CD39.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Nitric oxide donors increase mucus gel thickness in rat stomach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

The development of gastrointestinal-sparing nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

In vitro effects of picotamide on human platelet aggregation, the release reaction and thromboxane B2 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

"In vitro" and "ex vivo" effects of picotamide, a combined thromboxane A2-synthase inhibitor and -receptor antagonist, on human platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Effects of picotamide, an antiplatelet agent, on cardiovascular, events in 438 claudicant patients with diabetes: a retrospective analysis of the ADEP study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Pharmacological profile of G619, a new platelet aggregation inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

Differential Suppression of Thromboxane Biosynthesis by Indobufen and Aspirin in Patients With Unstable Angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.10.5.865

10.1517/13543784.10.5.865

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11322863